Abstract
Since their initial discovery, endothelial progenitor cells (EPCs) have held tremendous promise for cell therapy for a variety of cardiovascular diseases including pulmonary hypertension. The clinical experience to date suggests that circulating or bone marrow mononuclear cells and EPCs can induce neovascularization, and enhance cardiac repair after myocardial function, as well as improvements in the hemodynamic and functional status of patients with idiopathic pulmonary arterial hypertension. Although these results are promising, the overall magnitude of the clinical benefits seen in these trials appear to be rather modest. Indeed, strong experimental evidence points towards a reduction in mobilization and impairment in function of EPCs in preclinical models and patients with cardiac disease or with cardiovascular risk factors such as advanced age, type I and II diabetes, hypercholesterolemia, coronary artery disease, as well as other conditions such as pulmonary hypertension. Genetic engineering of EPCs ex vivo, prior to transplantation, is a promising cell-enhancement strategy for restoring the angiogenic potential of autologous, patient-derived cells. This review provides an update of the experimental studies that have used gene-modified EPC therapy to treat ischemic cardiovascular disease and pulmonary hypertension.
Keywords: Endothelial progenitor cells, gene therapy, ischemic cardiovascular disease, pulmonary hypertension, vascular regeneration
Current Vascular Pharmacology
Title:Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Volume: 10 Issue: 3
Author(s): Jessie R. Lavoie and Duncan J. Stewart
Affiliation:
Keywords: Endothelial progenitor cells, gene therapy, ischemic cardiovascular disease, pulmonary hypertension, vascular regeneration
Abstract: Since their initial discovery, endothelial progenitor cells (EPCs) have held tremendous promise for cell therapy for a variety of cardiovascular diseases including pulmonary hypertension. The clinical experience to date suggests that circulating or bone marrow mononuclear cells and EPCs can induce neovascularization, and enhance cardiac repair after myocardial function, as well as improvements in the hemodynamic and functional status of patients with idiopathic pulmonary arterial hypertension. Although these results are promising, the overall magnitude of the clinical benefits seen in these trials appear to be rather modest. Indeed, strong experimental evidence points towards a reduction in mobilization and impairment in function of EPCs in preclinical models and patients with cardiac disease or with cardiovascular risk factors such as advanced age, type I and II diabetes, hypercholesterolemia, coronary artery disease, as well as other conditions such as pulmonary hypertension. Genetic engineering of EPCs ex vivo, prior to transplantation, is a promising cell-enhancement strategy for restoring the angiogenic potential of autologous, patient-derived cells. This review provides an update of the experimental studies that have used gene-modified EPC therapy to treat ischemic cardiovascular disease and pulmonary hypertension.
Export Options
About this article
Cite this article as:
R. Lavoie Jessie and J. Stewart Duncan, Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension, Current Vascular Pharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157016112799959413
DOI https://dx.doi.org/10.2174/157016112799959413 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Current Molecular Medicine Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Clinical Values of Nitric Oxide Parameters from the Respiratory System
Current Medicinal Chemistry Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Preterm Birth: Long Term Cardiovascular and Renal Consequences
Current Pediatric Reviews Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Cardiac Complications in Hypertension and Diabetes: Role of Sympathetic Nervous Activity
Current Hypertension Reviews Diagnostics and Therapy of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitides
Current Pharmaceutical Design Factor XII, Kininogen and Plasma Prekallikrein in Abnormal Pregnancies
Current Drug Targets Increased Radioisotope Accumulation Around Pulmonary Arteriovenous Fistula Illustrated by Tc-99m-macroaggregated Albumin Scintigraphy and SPECT/CT in a Patient with Osler-Weber-Rendu Syndrome
Current Medical Imaging Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives
Current Pharmaceutical Design The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Evidence for, and Importance of, cGMP-Independent Mechanisms with NO and NO Donors on Blood Vessels and Platelets
Current Vascular Pharmacology Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews